News in brief - July 2014 (updated)

Other new launches, licence changes and updates relevant to general practice.

The new formulation of MabThera (rituximab) is given by subcutaneous injection into the abdominal wall over five minutes.
The new formulation of MabThera (rituximab) is given by subcutaneous injection into the abdominal wall over five minutes.
  • Halaven (eribulin) can now be used to treat locally advanced or metastatic breast cancer that has progressed after a single chemotherapy regimen.
  • Fomicyt (fosfomycin) is an intravenous antibiotic for the treatment of acute osteomyelitis, complicated UTI, nosocomial lower RTI, meningitis, and bacteraemia associated with these infections.
  • InVita D3 (colecalciferol) is a new oral vitamin D3 solution for use in osteoporosis and vitamin D deficiency.
  • Scopoderm (hyoscine hydrobromide) patches can now be bought without a prescription from pharmacies for the treatment of travel sickness. Each 1.5mg patch can be used for up to 72 hours.
  • Roche has launched a new subcutaneous formulation of MabThera (rituximab) indicated in adults with non-Hodgkin’s lymphoma. The new formulation is not approved for use in children or for the rheumatoid arthritis or polyangiitis indications.
  • The licensed indications of Gardasil (human papillomavirus vaccine) have been extended to include the prevention of premalignant anal lesions and anal cancer. 
  • The pneumococcal vaccine Pneumovax II has been renamed Pneumococcal Polysaccharide Vaccine Sanofi Pasteur MSD.

Follow MIMS on Twitter

Sign up for MIMS bulletins


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases